Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double‐blind studies

BACKGROUND AND PURPOSE: Humanized monoclonal antibody galcanezumab, which binds to calcitonin‐gene‐related peptide, has shown efficacy for episodic and chronic migraine prevention. These analyses evaluated galcanezumab response for migraine headache prevention in patients who previously failed onabo...

Descripción completa

Detalles Bibliográficos
Autores principales: Ailani, J., Pearlman, E., Zhang, Q., Nagy, A. J., Schuh, K., Aurora, S. K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028018/
https://www.ncbi.nlm.nih.gov/pubmed/31595600
http://dx.doi.org/10.1111/ene.14102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028018/
https://www.ncbi.nlm.nih.gov/pubmed/31595600
http://dx.doi.org/10.1111/ene.14102

Ejemplares similares